Jyong Biotech Ltd. (MENS)
NGM · Healthcare · Biotechnology
$2.05
+7.33%
Closing price as of 2026-10-28 · Source: TEK2day Finance
Key Metrics
Market Cap
$152.2M
Shares Outstanding
74.2M
Exchange
NGM
Currency
USD
About Jyong Biotech Ltd.
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (2.8M) | (2.8M) | (2.1M) | (2.6M) |
| Net Income | (6.6M) | (4.4M) | (3.0M) | (4.7M) |
| Diluted EPS | $-0.09 | $-0.06 | $-0.04 | N/A |